Related Experiment Videos
Endothelial function and the kidney. An emerging target for cardiovascular therapy
1Department of Nephrology and Hypertension, University Hospital Utrecht, The Netherlands.
Drugs
|January 1, 1997
Summary
Endothelial dysfunction contributes to kidney disease. Calcium antagonists show promise in treating acute renal ischemia, while combination therapy with ACE inhibitors may improve chronic kidney disease outcomes.
Area of Science:
- Nephrology
- Cardiovascular Science
- Pharmacology
Background:
- Endothelial dysfunction is a key factor in the early stages of acute and chronic kidney disease.
- Existing treatments like calcium antagonists, ACE inhibitors, and statins offer potential benefits.
Purpose of the Study:
- To explore the role of endothelial dysfunction in renal disease.
- To evaluate the efficacy of specific drug classes, particularly calcium antagonists and ACE inhibitors, in managing renal dysfunction.
Main Methods:
- Review of established pharmacological agents including calcium antagonists, angiotensin converting enzyme (ACE) inhibitors, and HMG CoA reductase inhibitors.
- Focus on the impact of these agents on endothelial dysfunction in the context of acute and chronic renal disease.
Main Results:
- Calcium antagonists are effective in mitigating acute renal ischemia linked to endothelial dysfunction.
- Combination therapy with calcium antagonists and ACE inhibitors may enhance treatment outcomes for chronic renal failure.
Conclusions:
- Targeting endothelial dysfunction is crucial for managing renal disease.
- Calcium antagonists offer significant benefits for acute renal ischemia.
- Combined calcium antagonist and ACE inhibitor therapy presents a promising strategy for chronic kidney disease.